Kum Ja Lee is an assistant professor of clinical pharmacy at the USC School of Pharmacy. She currently provides patient care and clinical services to hematology-oncology patients at the USC/Norris Comprehensive Cancer Center.
Dr. Lee received her Doctor of Pharmacy degree from USC in 1985. She then completed a residency in pharmacy practice at LAC/USC, joining the faculty of the USC School of Pharmacy in 1986. In 2001, she became a Board Certified Oncology Pharmacist. Dr. Lee provides lectures to third-year pharmacy students on lung cancer and on the organ toxicities of chemotherapy. She is a member of the Bone Marrow Transplant, BMT Critical Care Pathway and the Pain Management Committees at the Norris Comprehensive Cancer Center. She participated in developing the BMT critical pathways at the hospital.
Areas of Expertise (6)
Supportive Care of Hematology-Oncology and Stem-Cell Transplantation Patients
Pharmacist's Role in Critical Care Pathways
Parenteral Drug Compatibilities
Pharmacokinetics of Antibiotics
Pain Management/Palliative Care
Selected Articles (3)
Chang J, Douer D, Aldoss I, Vahdani G, Jeong AR, Ghaznavi Z, Zhang S, Yaghmour G, Lee KJ, Weissman A, Akhtari M.
2019 The Philadelphia chromosome is associated with a poor prognosis in acute lymphoblastic leukemia (ALL). While hematopoietic stem cell transplantation (HSCT) has been regarded as a favorable treatment option in adult Philadelphia-positive (Ph+) ALL, its benefit is less clear in the era of newer generation tyrosine kinase inhibitors (TKIs) like dasatinib.
Lee KJ, Chow V, Weissman A, Tulpule S, Aldoss I, Akhtari M.
2016 Adults with relapsed or refractory B-cell acute lymphoblastic leukemia have a dismal prognosis with a short median overall survival that can be measured in months. Because most patients will have chemotherapy-resistant disease, allogeneic hematopoietic stem cell transplantation remains the only potentially curative treatment. Despite advances in current management, patients continue to have poor outcomes and lack of durable responses. Thus, new therapies with alternative modes of actions are currently being investigated. Blinatumomab is a novel bispecific T-cell engager that simultaneously binds CD3-positive cytotoxic T-cells and CD19-positive B-cells, resulting in selective lysis of tumor cells. It has shown promising results in patients with relapsed or refractory acute lymphoblastic leukemia or those achieving hematologic response with persistent minimum residual disease. Future clinical trials will answer questions regarding its optimal place in the treatment paradigm. Dose-limiting toxicities include immunological toxicities and cytokine release syndrome. However, most patients tolerate the therapy relatively well. This review will focus on the pharmacology, clinical efficacy, and safety of blinatumomab in the treatment of adult B-cell acute lymphoblastic leukemia while highlighting its unique drug warnings and toxicity management.
Kim JM, Kim SS, Kim JH, Kim MK, Kim TN, Lee SH, Lee CW, Park JY, Kim ES, Lee KJ, Choi YS, Kim DK, Kim IJ.
2019 There is limited information regarding the optimal third-line therapy for managing type 2 diabetes mellitus (T2DM) that is inadequately controlled using dual combination therapy. This study assessed the efficacy and safety of pioglitazone or glimepiride when added to metformin plus alogliptin treatment for T2DM.